forced expiratory volume

(redirected from FEV1)
Also found in: Medical, Acronyms.

forced expiratory volume

[¦fȯrst ik¦spī·rə‚tȯr·ē ′väl·yəm]
(medicine)
During the performance of a forced vital capacity measurement, the volume of exhaled gas over a specific time interval.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
There was significant increase in VC, FVC, FEV1, FEV1/FVC and MVV values of women after 24 week exercise period (p < 0.01) (Table 1).
FEV1 is low in people who have chronic obstructive pulmonary disease or who are regularly exposed to cigarette smoke.
Mean values +- SD of FVC Pred, FEV1 Pred and FEV1/FVC in our study were 2.99+-0.61, 2.52+-0.52 and 64.24+-17.52 respectively.
[7] concluded in adult males that the values of FEV1, FVC, and MVV were significantly reduced in obese males similar to our study, but FEV1/FVC ratio, PEFR, and FEF 25-75% show insignificant changes.
The main finding of this study is that the BODE staging system, [6] which includes in addition to FEV1 other physiologic and clinical variables, helps to better predict hospitalisation in patients with COPD.
Coefficient values for (B), (C), and (D) amount to Prob (t) values of 0.034, 0.098, and 0.032, respectively, and the probability that the values of independent variables (FVC, FEV1, and PEF) will be 0 is 3.84%, 9.8%, and 3.2%, respectively.
9The measurement of pulmonary function related parameters including Force Vital limit (FVC), Force Expiratory Volume in First Second (FEV1), FEV1/FVC, Peak Expiratory Flow (PEF), Force Expiratory Flow at 25%, Force Expiratory Flow at 75% and Force Expiratory Flow at 25-75% was done.
Our findings for FVC, FEV1, FIVC, and FIV1 are in concordance with various previous researchers as Koral et al.
Bhatt, M.D., from the University of Alabama at Birmingham, and colleagues examined the discriminative accuracy of various FEV1:FVC fixed thresholds for predicting COPD-related hospitalization and mortality using pooled data for 24,207 adults from four U.S.
Patients in the etokimab arm rapidly improved their forced exhaled volume in one second, or FEV1, which is a measure of lung function, with an 8% FEV1 improvement over placebo at Day 2, which was sustained through Day 64 with an 11% increase over placebo.